Variation of specific activities of 68Ga-aquibeprin and 68Ga-avebetrin enables selective PET imaging of different expression levels of integrins α5β1 and αvβ3

Journal of Nuclear Medicine

Volumn 57, Issue 10, 2016, Pages 1618-1624

  Notni, Johannes ^a   Steiger, Katja ^a   Hoffmann, Frauke ^a   Reich, Dominik ^a   Schwaiger, Markus ^a   Kessler, Horst ^a   Wester, Hans Jürgen ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

68Ga; Positron emission tomography; Preclinical imaging; Receptor density

Indexed keywords

AQUIBEPRIN GA 68; AVEBETRIN GA 68; GALLIUM 68; TIN DERIVATIVE; TIN DIOXIDE; TRACER; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 5; VITRONECTIN RECEPTOR; 68GA-AQUIBEPRIN; 68GA-AVEBETRIN; COORDINATION COMPOUND;

ADRENAL GLAND; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG UPTAKE; EX VIVO STUDY; EYE; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; ISOTOPE LABELING; MELANOMA; MOUSE; NONHUMAN; PH; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; CHEMISTRY; GENE EXPRESSION REGULATION; METABOLISM; PROCEDURES; RADIOCHEMISTRY; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; COORDINATION COMPLEXES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTEGRIN ALPHA5BETA1; INTEGRIN ALPHAVBETA3; MICE; POSITRON-EMISSION TOMOGRAPHY; RADIOCHEMISTRY; TISSUE DISTRIBUTION;

EID: 84991401408     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.116.173948     Document Type: Article

References (39)

1. van Grieken R, de Bruin M. Nomenclature for radioanalytical chemistry. Pure Appl Chem. 1994;66:2513-2526.
2. 177Lu by HPLC. Curr Radiopharm. 2015;8:119-122.
3. Lambert R, Willenbrock R, Tremblay J, et al. Receptor imaging with atrial natriuretic peptide part 1: high specific activity iodine-123-atrial natriuretic peptide. J Nucl Med. 1994;35:628-637.
4. Kung MP, Kung HF. Mass effect of injected dose in small rodent imaging by SPECT and PET. Nucl Med Biol. 2005;32:673-678.
5. 177Lu-octreotate really achieve relevant somatostatin receptor saturation in target tumor lesions?: Insights from intra-therapeutic receptor imaging in patients with metastatic gastroenteropancreatic neuroendocrine tumors. EJNMMI Res. 2013;3:82.
6. Breeman WAP, Kwekkeboom DK, Kooij PPM, et al. Effect of dose and specific activity on tissue distribution of indium-111-pentetreotide in rats. J Nucl Med. 1995;36:623-627.
7. 68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours: impact of peptide mass. Nucl Med Biol. 2010;37:265-275.
8. 68Ga-labeled peptide. Nucl Med Biol. 2008;35:529-536.
9. Hicks RJ. The difference between medicine and magic is that magicians know what they are doing. Eur J Nucl Med Mol Imaging. 2015;42:1-4.
10. Levi H. George Hevesy and his concept of radioactive indicators: in retrospect. Eur J Nucl Med. 1976;1:3-10.
11. Eckelman WC. True radiotracers: are we approaching theoretical specific activity with Tc-99m and I-123? Nucl Med Biol. 2008;35:523-527.
12. 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2012;39:50-56.
13. 3]octreotide is dependent on the peptide amount. Eur J Nucl Med. 1999;26:693-698.
14. 68Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET. Eur J Nucl Med Mol Imaging. 2010;37:1345-1355.
15. 68Ga-labeled bombesin(6-14) analog. J Nucl Med. 2005;46:691-699.
16. Froidevaux S, Calame-Christe M, Schuhmacher J, et al. A gallium-labeled DOTA-alpha-melanocyte-stimulating hormone analog for PET imaging of melanoma metastases. J Nucl Med. 2004;45:116-123.
17. 111In-DTPA-D-Phe1-octreotide in tumor-bearing nude mice: influence of amount injected and route of administration. Nucl Med Biol. 2003;30:253-260.
18. Konijnenberg MW, Breeman WAP, de Blois E, et al. Therapeutic application of CCK2R-targeting PP-F11: influence of particle range, activity and peptide amount. EJNMMI Res. 2014;4:47.
19. Tolmachev V, Wållberg H, Sandström M, Hansson M, Wennborg A, Orlova A. Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels. Eur J Nucl Med Mol Imaging. 2011;38:531-539.
20. 111In-DOTA-Z (EGFR:2377) Affibody molecule: aspect of the injected tracer amount. Eur J Nucl Med Mol Imaging. 2010;37:613-622.
21. 3. Nucl Med Biol. 2013;40:33-41.
22. 68Ga-avebetrin. J Nucl Med. 2016;57:460-466.
23. Baranyai Z, Reich D, Vágner A, et al. A shortcut to high-affinity Ga-68 and Cu-64 radiopharmaceuticals: one-pot click chemistry trimerisation on the TRAP platform. Dalton Trans. 2015;44:11137-11146.
24. Notni J, Šimeček J, Wester HJ. Phosphinic acid functionalized polyazacycloalkane chelators for radiodiagnostics and radiotherapeutics: unique characteristics and applications. ChemMedChem. 2014;9:1107-1115.
25. Šimeček J, Wester HJ, Notni J. Copper-64 labelling of triazacyclononane-triphosphinate chelators. Dalton Trans. 2012;41:13803-13806.
26. Notni J, Šimeček J, Hermann P, Wester HJ. TRAP, a powerful and versatile framework for gallium-68 radiopharmaceuticals. Chem Eur J. 2011;17:14718-14722.
27. Šimeček J, Schulz M, Notni J, et al. Complexation of metal ions with TRAP (1,4,7-triazacyclononane-phosphinic acid) ligands and 1,4,7-triazacyclononane-1,4,7-triacetic acid: phosphinate-containing ligands as unique chelators for trivalent gallium. Inorg Chem. 2012;51:577-590.
28. Poty S, Désogère P, Šimeček J, et al. MA-NOTMP: a triazacyclononane trimethylphosphinate based bifunctional chelator for gallium radiolabelling of biomolecules. ChemMedChem. 2015;10:1475-1479.
29. Šimeček J, Zemek O, Hermann P, Wester HJ, Notni J. A monoreactive bifunctional triazacyclononane-phosphinate chelator with high selectivity for gallium-68. ChemMedChem. 2012;7:1375-1378.
30. 68Ga generator eluates? ChemMedChem. 2013;8:95-103.
31. 68Ga labelling properties. Molecules. 2015;20:13112-13126.
32. Notni J, Pohle K, Wester HJ. Comparative gallium-68 labeling of TRAP-, NOTA-, and DOTA-peptides: practical consequences for the future of gallium-68-PET. EJNMMI Res. 2012;2:28.
33. 18F-galacto-RGD and can be produced with high specific activity in a cGMP/GRP compliant automated process. Nucl Med Biol. 2012;39:777-784.
34. Adamis AP, Aiello LP, D'Amato RA. Angiogenesis and ophthalmic disease. Angiogenesis. 1999;3:9-14.
35. 1 in the regulation of corneal neovascularization. Exp Eye Res. 2007;85:356-365.
36. Zhang H, Li C, Baciu PC. Expression of integrins and MMPs during alkaline-burn-induced corneal angiogenesis. Invest Ophthalmol Vis Sci. 2002;43:955-962.
37. Le Gat L, Gogat K, van den Berghe L, et al. The β3 integrin gene is expressed at high levels in the major haematopoietic and lymphoid organs, vascular system, and skeleton during mouse embryo development. Cell Commun Adhes. 2003;10:129-140.
38. 68Ga-NOPO-c(RGDfK). Mol Pharm. 2014;11:1687-1695.
39. vβ3 integrin expression and facile radiosynthesis. J Nucl Med. 2011;52:1276-1284.